InMed Pharmaceuticals has completed its merger with privately held Mentari Therapeutics, and the combined company will begin trading on the Nasdaq Capital Market under the ticker symbol MTRI at market open on Monday, November 9, 2026. The deal was announced as completed on November 6, 2026, and the combined company will operate under the Mentari Therapeutics name.
The transaction is a reverse merger: a private biotech company, Mentari, has taken over the Nasdaq listing of a public company, InMed, rather than going public through an initial public offering. Before the merger closed, Mentari completed previously announced private financings totalling approximately $490 million in gross proceeds, including the conversion of $50 million in previously issued convertible notes plus accrued interest. Backers in the financing included Fairmount, Blackstone Multi-Asset Investing, Wellington Management, a16z Bio + Health and Perceptive Advisors. The funding is expected to support development into 2029.
How the Deal Was Structured
The mechanics of the transaction are worth understanding, because they show how reverse mergers actually work. Immediately before closing, InMed redomesticated from British Columbia, Canada, to the State of Nevada, and effected a 1-for-10 reverse stock split on November 4, 2026. Each outstanding share of pre-merger Mentari common stock was then converted into approximately 0.20065 shares of the combined company's common stock, as adjusted for the reverse split.
The ownership outcome is stark: InMed's pre-merger shareholders retain about 1.5 percent of the combined entity, while Mentari's shareholders and its new investors hold the rest. InMed shareholders of record as of November 5, 2026 also received one non-transferable contingent value right (CVR) per share — a security that pays out only if certain future events occur, typically tied to the value of the legacy business. In practice, the CVR is the mechanism that gives the old shareholders some upside if InMed's legacy assets ever produce value, without giving them a meaningful stake in the new company.
What Mentari Does
Mentari Therapeutics, headquartered in Waltham, Massachusetts, is a clinical-stage biotechnology company developing next-generation therapies for the prevention of migraine, a condition the company says affects more than 1 billion people globally. Its lead programs are MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both PACAP and CGRP.
The science targets a pathway distinct from the established CGRP migraine drugs that already dominate the market. MT-001 is aimed at Phase 2 proof-of-concept data around 2028, while MT-002 is expected to produce Phase 1 data around 2027. Both candidates remain early-stage and unproven, and their effectiveness, safety and eventual regulatory outcomes are subject to clinical evaluation. The merger shifts the company's focus entirely away from InMed's previous work in cannabinoid-based drug development.
What Is a Reverse Merger — and Why Use One?
A reverse merger is a way for a private company to become public without an IPO. Instead of filing a prospectus, marketing shares to new investors and pricing an offering, the private company merges into an already-listed public company and takes over its ticker. The private company's shareholders end up owning most of the combined entity, and the public company's shell — its listing, its reporting history, its shareholder base — becomes the vehicle.
The advantages are speed and certainty: the deal can close in months, and the financing can be raised privately alongside it, as Mentari did with its $490 million in private financings. The disadvantages are also real. The listing comes with a legacy shareholder base, legacy liabilities and a share price history that may not reflect the new business at all. Reverse mergers also carry a reputation problem in some corners of the market, because the route has historically been used by companies that could not pass IPO scrutiny — which is why the quality of the incoming business and its investors matters so much. In this case, the calibre of the financing syndicate is the strongest signal about how the market views the deal.
Why It Matters for Founders and Investors
For biotech founders, the Mentari deal is a reminder that the IPO is not the only route to a public listing, and that in a difficult IPO market a well-funded reverse merger can be the faster path. But the economics are unforgiving: the incoming company's investors need to be large and credible enough to carry the valuation, and the legacy shareholders are typically left with almost nothing. For investors, the November 9 debut under MTRI is the moment the story resets — the ticker changes, the business changes, and the only thing that matters from here is whether MT-001 and MT-002 produce clinical data. Everything before that is corporate plumbing.
Angeled.com connects founders with investors.
Pulse2, "Mentari Therapeutics Completes InMed Pharmaceuticals Merger Following Approximately $490 Million In Financing," November 8, 2026
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



